AKT1 and glioma: But for PTPN9, which appears to be a tumor suppressor, leads to decreased glioma cell viability by reducing the phosphorylation of EGFR and cooperating with BRAF (V600E) inhibitors to restrain MAPK and AKT signaling (101).